目的: 探讨联合检测肿瘤标志物ProGRP、CEA、CYFRA21-1、NSE、SCC对良恶性胸腔积液的诊断价值。方法: 收集2020年1月-2021年1月在包头医学院第一附属医院收治的确诊为良性胸腔积液(BPE,87例)和恶性胸腔积液(MPE,44例)患者,共131例。应用化学发光法检测患者胸腔积液中ProGRP、CEA、CYFRA21-1、NSE以及SCC的浓度,比较良恶性胸腔积液中肿瘤标志物的水平,将5种肿瘤标志物以不同的方式组合,通过受试者工作特征(ROC)曲线分析比较不同联合方式的诊断价值。结果: ProGRP+CEA+CYFRA21-1+NSE 联合方式对应的ROC曲线下面积(AUC)最大(0.841),其约登指数最大时,灵敏度77.3 %,特异度85.1 %,阳性似然比5.188,阴性似然比0.267,诊断价值最高。结论: 通过联合检测不同组合的肿瘤标志物发现,ProGRP+CEA+CYFRA21-1+NSE的组合形式在诊断效能、特异度、灵敏度、阳性似然比、阴性似然比等方面优于其他组合,在鉴别诊断胸腔积液性质方面有重要参考价值。
Objective: To investigate the diagnostic value of combined detection of tumor markers ProGRP, CEA, CYFRA21-1, NSE and SCC in the diagnosis of benign and malignant pleural effusion.Methods: A total of 131 cases of pleural effusion diagnosed as benign pleural effusion and malignant pleural effusion in the First Affiliated Hospital of Baotou Medical College from January 2020 to January 2021 were collected, including 87 cases of BPE and 44 cases of MPE. The concentrations of ProGRP, CEA, CYFRA21-1, NSE and SCC in pleural effusion of patients were detected by chemiluminescence method, and the levels of tumor markers in benign and malignant pleural effusion were compared. Five tumor markers were combined in different ways, and the diagnostic values of different combinations were compared by receiver operating characteristic (ROC) curve analysis. Results: The area under the ROC curve (AUC) corresponding to the combination of ProGRP+CEA+CYFRA21-1+NSE was the largest (0.841), and the sensitivity was 77.3 %, the specificity was 85.1 %, the positive likelihood ratio was 5.188, and the negative likelihood ratio was 0.267, with the highest diagnostic value. Conclusion: The combination of ProGRP+CEA+CYFRA21-1+NSE is superior to other combinations in terms of diagnostic efficacy, specificity, sensitivity, positive likelihood ratio and negative likelihood ratio, and has important reference value in the differential diagnosis of pleural effusion.
[1] 伍燕兵, 杜莹, 逯勇, 等. 胸腔积液病因分析[J]. 中国呼吸与危重监护杂志, 2017, 16(5): 490-494.
[2] 陈静. 胸腔积液病因分析及临床治疗[J]. 中国实用医药, 2014, 9(30): 83.
[3] 吴迪, 刘盛国, 杨凯, 等. 胸腔积液的病因分布及临床特点[J]. 广东医学, 2020, 41(14): 1459-1463.
[4] Dixit R, Agarwal KC, Gokhroo A, et al. Diagnosis and management options in malignant pleural effusions[J]. Lung India, 2017, 34(2): 160-166.
[5] Wu YB, Xu LL, Wang XJ, et al. Diagnostic value of medical thoracoscopy in malignant pleural effusion[J]. BMC Pulm Med, 2017, 17(1): 109.
[6] Porcel JM. Malignant pleural effusions because of lung cancer[J]. Curr Opin Pulm Med, 2016, 22(4): 356-361.
[7] 孙美琪, 张薇, 郝倩文, 等. 肿瘤标志物对良恶性胸腔积液鉴别的研究进展[J]. 实用肿瘤杂志, 2020, 35(3): 278-283.
[8] 段云, 康钰龄, 郑虹蕾, 等. fPSA %、PSAD、proGRP水平对前列腺癌及骨转移的诊断价值[J]. 西部医学, 2021, 33(4): 605-610.
[9] 陈阳育, 徐莉莉, 伍燕兵, 等. 血清及胸腔积液中四种肿瘤标志物联合应用对良恶性肿瘤鉴别诊断价值的评估[J]. 中华肿瘤防治杂志, 2021, 28(3): 212-222.
[10] Lepusc M, Vivero M. Updates in effusion cytology[J]. Surg Pathol Clin, 2018, 11(3): 523-544.
[11] Yang Y, liu YL, Shi HZ. Diagnostic accuracy of combinations of tumor markers for malignant pleural effusion: an updated meta-analysis[J]. Respiration, 2017, 94(1): 62-69.
[12] 李东风, 于卫民. 食管鳞癌患者血清CEA、ProGRP、CA19-9联合检测的诊断价值[J]. 中国卫生工程学, 2021, 20(02): 265-267.
[13] 屈雪, 秦晓松. 胃泌素释放肽前体、癌胚抗原和神经元特异性烯醇化酶在食管癌诊断中的价值研究[J]. 中国肿瘤外科杂志, 2020, 12(2): 144-147.
[14] 屈重行, 葛瑞瑞, 陈文霞, 等. 胃癌患者血清CYFRA21-1、TuM2-PK、ProGRP的表达和意义[J]. 中国卫生工程学, 2021, 20(2): 210-213.
[15] 梁改红, 陈艳红. 外周血亲环素B、胃泌素释放肽前体、维生素D结合蛋白在胃癌根治术病人中的表达及对术后复发的影响[J]. 安徽医药, 2021, 25(5): 970-974.
[16] Wojcik E, Kulpa JK. Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response[J]. Lung Cancer (Auckl), 2017 ,8:231-240.
[17] Kim H, Jung HI, Kwon SH, et al. Preoperative neutrophil-lymphocyte ratio and CEA is associated with poor prognosis in patients with synchronous colorectal cancer liver metastasis[J]. Ann Surg Treat Res, 2019, 96(4): 191-200.
[18] 李振雪, 刘大敏, 刘宁, 等. 联合检测CEA、CA15-3、CA19-9、β-HCG、TPA 5种肿瘤标志物对鉴别良恶性胸腔积液的价值[J]. 中国实验诊断学, 2019, 23(6): 947-950.
[19] Dal Bello MG, Filiberti RA, Alama A, et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients[J]. J Transl Med, 2019, 17(1): 74.
[20] Guo wH, Yuan L, Ma L, et al. The diagnostic efficacy of CYFRA21-1 on intrahepatic cholangiocarcinoma: A meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2019, 43(3): 266-272.
[21] Ren H, Hu Y, Xie T, et al. Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer[J]. Oncol Lett, 2019, 18(4): 4167-4175.
[22] Yangc F, Jia Y, yanc H. The application of CYFRA21-1 in cervical lesions screening in high-risk human papillomavirus infected women[J]. Ginekol Pol, 2016, 87(9): 617-620.
[23] 罗莉, 刘玉荣, 苏磊. 食管鳞癌患者血清TK1与SCCA表达及其预后价值[J]. 中华肿瘤防治杂志, 2020, 27(5): 353-359.
[24] 刘涛, 杨燕, 刘博, 等. 联合检测胸腹腔积液sCD44V6, CEA, CYFRA21-1, CA199, NSE, CA125对良恶性疾病鉴别诊断价值研究[J]. 现代检验医学杂志, 2020, 35(2): 53-55.
